新型β⁃内酰胺酶抑制剂复合制剂头孢吡肟/他尼硼巴坦临床药学研究进展  

The clinical pharmacological review of cefepime/taniborbactam:a new typeβ⁃lactamase inhibitor complex formulation

作　　者：辛明明 马序竹[1] 董晶[1] 林明贵 XIN Ming-ming;MA Xu-zhu;DONG Jing;LIN Ming-gui(Infectious diseases Department,School of Clinical Medicine,Beijing Tsinghua Changgung Hospital,Tsinghua University,Beijing 102218,China)

机构地区：[1]清华大学附属北京清华长庚医院,清华大学临床医学院,感染性疾病科,北京102218

出　　处：《中国新药杂志》2024年第21期2272-2277,共6页Chinese Journal of New Drugs

摘　　要：细菌耐药在全球范围内呈指数级增长,尤其是碳青霉烯耐药革兰阴性菌,有效的治疗药物十分有限。他尼硼巴坦是一种新型环状硼酸酯类β⁃内酰胺酶抑制剂,对丝氨酸和金属⁃β⁃内酰胺酶(Ambler类A,B,C和D)的活性具有较强的抑制作用,其与头孢吡肟组合进行新药研发,有望拓展这一用药需求。本文通过文献回顾,对头孢吡肟/他尼硼巴坦的作用机制、药效学、药动学及临床研究等进行综述。Bacterial resistance is increasing exponentially worldwide,especially in carbapenem resistant Gram negative bacteria,but effective therapeutic drugs are very limited.Taniborbactam is a novel cyclic borate esterβ⁃lactamase inhibitor.It has a strong inhibitory effect on serine and metallo⁃β⁃lactamases(Ambler classes A,B,C and D).Currently,taniborbactam is combined with cefepime for new drug development,with the potential to address this medication demand.This article provides a review on the mechanism,pharmacodynamics,and pharmacokinetic clinical studies in cefepime/taniborbactam.

关 键 词：β⁃内酰胺酶抑制剂 头孢吡肟 他尼硼巴坦 药效学 药动学 

分 类 号：R969[医药卫生—药理学]